Myovant Sciences Ltd. (NYSE:MYOV) has a beta value of 2.84 and has seen 0.59 million shares traded in the last trading session. The company, currently valued at $2.49B, closed the last trade at $26.75 per share which meant it lost -$0.24 on the day or -0.89% during that session. The MYOV stock price is -15.51% off its 52-week high price of $30.90 and 49.83% above the 52-week low of $13.42. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.72 million shares traded. The 3-month trading volume is 711.62K shares.
The consensus among analysts is that Myovant Sciences Ltd. (MYOV) is an Overweight stock at the moment, with a recommendation rating of 2.00. 0 analysts rate the stock as a Sell, while 1 rate it as Overweight. 1 out of 5 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.39.
Myovant Sciences Ltd. (NYSE:MYOV) trade information
Sporting -0.89% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Friday, 09/03/21 when the MYOV stock price touched $26.75 or saw a rise of 2.27%. Year-to-date, Myovant Sciences Ltd. shares have moved -3.15%, while the 5-day performance has seen it change 13.35%. Over the past 30 days, the shares of Myovant Sciences Ltd. (NYSE:MYOV) have changed 28.17%. Short interest in the company has seen 3.03 million shares shorted with days to cover at 4.19.
Wall Street analysts have a consensus price target for the stock at $33.25, which means that the shares’ value could jump 19.55% from current levels. The projected low price target is $18.00 while the price target rests at a high of $55.00. In that case, then, we find that the current price level is -105.61% off the targeted high while a plunge would see the stock lose 32.71% from current levels.
Myovant Sciences Ltd. (MYOV) estimates and forecasts
Figures show that Myovant Sciences Ltd. shares have outperformed across the wider relevant industry. The company’s shares have gained 20.99% over the past 6 months, with this year growth rate of 20.14%, compared to 7.50% for the industry. Other than that, the company has, however, increased its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 48.00% and 41.50% for the next quarter. Revenue growth from the last financial year stood is estimated to be 277.30%.
5 analysts offering their estimates for the company have set an average revenue estimate of $63.81 million for the current quarter. 5 have an estimated revenue figure of $61.52 million for the next quarter concluding in Dec 2021.
Myovant Sciences Ltd. is expected to release its next earnings report between November 10 and November 15 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Myovant Sciences Ltd. (NYSE:MYOV)’s Major holders
Insiders own 60.22% of the company shares, while shares held by institutions stand at 38.55% with a share float percentage of 96.89%. Investors are also buoyed by the number of investors in a company, with Myovant Sciences Ltd. having a total of 145 institutions that hold shares in the company. The top two institutional holders are Wellington Management Group, LLP with over 5.65 million shares worth more than $116.37 million. As of Mar 30, 2021, Wellington Management Group, LLP held 6.18% of shares outstanding.
The other major institutional holder is Janus Henderson Group PLC, with the holding of over 5.24 million shares as of Mar 30, 2021. The firm’s total holdings are worth over $107.82 million and represent 5.73% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Janus Henderson Global Life Sciences Fund and Lord Abbett Developing Growth Fund. As of Mar 30, 2021, the former fund manager holds about 1.46% shares in the company for having 1.34 million shares of worth $27.53 million while later fund manager owns 1.19 million shares of worth $27.7 million as of Jan 30, 2021, which makes it owner of about 1.30% of company’s outstanding stock.